Addressing Climate Change

Addressing Climate Change Challenges Through Biotechnology

There are more than 5 trillion pieces of plastic floating in our oceans. The U.S. transportation sector leads all other sectors in greenhouse gas emissions. Diseases that thrive in hot weather are killing important staple crops. Our reliance on products derived from fossil fuels is harming our planet.

Climate change is real but through biotechnology, we can meet these challenges head-on by making the same reliable plastics, foods, and fuels with less environmental impact.

Addressing Climate Change

Strengthening the Bioeconomy

Growing Trust in Innovation

Stay Informed. Current News in the Ag & Environment Sector

Climate Change Efforts in the Industry

Explore Latest News

Ag & Environment Efforts in the Industry

Explore Latest News

Press Releases

BIO Applauds FTC Settlement Decision

September 1, 2023

Yesterday the Federal Trade Commission (FTC) announced the decision to settle its Amgen-Horizon merger challenge. The settlement will give the Commission the relief it needs to protect competition, while allowing rare disease patients to enjoy the deal's pro-competitive benefits without delay. BIO…

BIO Podcast 2023 Fall Season Launch

August 30, 2023

New Season of I am BIO Podcast Covers Birds, Bees, and Bugs Fall 2023 season explores biotech solutions for wildlife conservation, bee health, drug-resistant bugs, and more Washington – (Aug. 30, 2023) – Save the date―the Biotechnology Innovation Organization will launch the fall season of the I…

BIO Statement on CMS Announcement of First 10 Drugs Subject to Price Controls Under IRA

August 29, 2023

The Biden Administration today unveiled the first 10 prescription drugs that will be subject to price controls under the Inflation Reduction Act (IRA). Rachel King, BIO interim President and CEO, made the following statement: The Medicare price control provisions of the IRA are already…

Subscribe to GoodDay BIO

Receive the best resource for the biotech industry with Good Day BIO, the only daily newsletter at the intersection of biotech, politics and policy.

Letters, Comments & Testimony

BIO Comments to FDA on Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products

August 3, 2023

In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.

BIO Comments on the NIH Technology Transfer Workshop

August 1, 2023

BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.

BIO Comment on EU Compulsory Licensing Legislation

July 31, 2023